• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Meltzer Leslie

    9/2/25 10:12:24 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    MELTZER LESLIE

    (Last) (First) (Middle)
    C/O APELLIS PHARMACEUTICALS, INC.
    100 FIFTH AVENUE, 3RD FLOOR

    (Street)
    WALTHAM MA 02451

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/26/2025
    3. Issuer Name and Ticker or Trading Symbol
    Apellis Pharmaceuticals, Inc. [ APLS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Research and Development
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ David Watson, attorney-in-fact for Leslie Meltzer 09/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $APLS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLS

    DatePrice TargetRatingAnalyst
    5/9/2025$23.00Buy → Neutral
    BofA Securities
    5/9/2025$52.00Strong Buy → Outperform
    Raymond James
    4/29/2025$44.00Overweight
    Cantor Fitzgerald
    12/17/2024$36.00Buy → Neutral
    Goldman
    11/21/2024$31.00Equal-Weight
    Morgan Stanley
    10/25/2024$25.00Sector Perform
    RBC Capital Mkts
    10/16/2024Sector Outperform
    Scotiabank
    10/16/2024Outperform
    William Blair
    More analyst ratings

    $APLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Research and Development Meltzer Leslie was granted 61,804 shares (SEC Form 4)

    4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    9/2/25 10:13:46 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Meltzer Leslie

    3 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    9/2/25 10:12:24 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Francois Cedric sold $6,352,743 worth of shares (225,000 units at $28.23) (SEC Form 4)

    4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    8/29/25 4:19:34 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    Leadership Updates

    Live Leadership Updates

    View All

    Apellis Announces Craig Wheeler to Join the Board of Directors

    WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. "We are thrilled to welcome Craig to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Craig is a seasoned leader, who has successfully grown biopharmaceutical companies into strong commercial organizations with robust pipelines

    4/21/25 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

    Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

    3/20/25 8:00:00 AM ET
    $APLS
    $BIIB
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Apellis Announces Keli Walbert to Join the Board of Directors

    WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. "We are delighted to welcome Keli to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Keli has a proven track record of successfully bringing novel medicines to patients as well as a respected reputation among industry leaders for her strategic thinking and innovation. Her deep commercial expertise will be invaluable as we c

    1/10/25 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Apellis Pharmaceuticals Inc.

    SCHEDULE 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    8/12/25 10:34:26 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Apellis Pharmaceuticals Inc.

    10-Q - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

    7/31/25 6:52:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Apellis Pharmaceuticals Inc.

    8-K - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

    7/1/25 7:09:33 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

    WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Date/Time: Wednesday, September 3, 2025 at 8:45 a.m. ET Cantor Global Healthcare Conference Date/Time: Thursday, September 4, 2025 at 8:35 a.m. ET Baird Global Healthcare ConferenceDate/Time: Tuesday, September 9, 2025 at 10:15 a.m. ET The live conference webcasts will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcasts will be available for approximately 30 days f

    8/27/25 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which Apellis receives up to $300 million for 90% of ex-U.S. royalties of Aspaveli® (pegcetacoplan)Generated $178 million in 2Q 2025 revenues, including $171 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 6% quarter-over-quarter, with U.S. net product revenue of $151 millionCash and cash equivalents of $370 million as of June 30, 2025; existing cash, $275 million payment from Sobi, and future product sales expected to be sufficient to fund business to sustainable

    7/31/25 7:05:08 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

    Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant C3G disease recurrence Well-established safety profile, consistent across >2,200 patient years in approved indications C3G and primary IC-MPGN are rare kidney diseases with high risk of kidney failure Conference call tomorrow at 8:00 a.m. ET WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacopla

    7/28/25 7:19:32 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Apellis Pharmaceuticals downgraded by Raymond James with a new price target

    Raymond James downgraded Apellis Pharmaceuticals from Strong Buy to Outperform and set a new price target of $52.00

    5/9/25 8:40:54 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Pharmaceuticals downgraded by BofA Securities with a new price target

    BofA Securities downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $23.00

    5/9/25 8:40:54 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Apellis Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $44.00

    4/29/25 8:10:45 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

    Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

    5/17/21 11:09:40 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/14/24 1:28:32 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    Financials

    Live finance-specific insights

    View All

    Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which Apellis receives up to $300 million for 90% of ex-U.S. royalties of Aspaveli® (pegcetacoplan)Generated $178 million in 2Q 2025 revenues, including $171 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 6% quarter-over-quarter, with U.S. net product revenue of $151 millionCash and cash equivalents of $370 million as of June 30, 2025; existing cash, $275 million payment from Sobi, and future product sales expected to be sufficient to fund business to sustainable

    7/31/25 7:05:08 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

    Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant C3G disease recurrence Well-established safety profile, consistent across >2,200 patient years in approved indications C3G and primary IC-MPGN are rare kidney diseases with high risk of kidney failure Conference call tomorrow at 8:00 a.m. ET WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacopla

    7/28/25 7:19:32 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

    WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines c

    7/24/25 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care